Skip to main content

Novartis to purchase British biotech Gyroscope, a gene-therapy company

The deal for Gyroscope is Novartis’s first acquisition since it agreed to sell a large stake in Roche back to its crosstown rival for $20.7 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.